Skip to content

MBX Biosciences

US · MBX #2567 by market cap Listed 2024
49.55 -3.86 -7.23%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Company notice
    4: MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Pescovitz Ora H.
    SEC · 2026/6/5
  • Rating change
    MBX Biosciences, Inc. (MBX) Gets a Buy From Mizuho Securities
    TipRanks · 2026/8/8
  • Company notice
    MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Hawryluk P. Kent
    SEC · 2026/5/9
  • Rating change
    Guggenheim Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $150
    Market Newswire · 2026/10/2
  • Rating change
    Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $84
    Market Newswire · 2026/10/12
  • Rating change
    Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $70
    Market Newswire · 2026/8/13
  • Company notice
    4: MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Hoerter Steven L.
    SEC · 2026/8/4
  • Company notice
    MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Hoerter Steven L.
    SEC · 2026/11/12
  • Rating change
    Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $88
    Market Newswire · 2026/8/7
  • Rating change
    Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91
    Market Newswire · 2026/8/8
  • Rating change
    J.P. Morgan Maintains MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $88
    Market Newswire · 2026/8/21
  • Company notice
    4: MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L.
    SEC · 2026/6/5
  • Guggenheim Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $150
    Market Newswire · 2026/10/12
  • Rating change
    LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $121
    Market Newswire · 2026/8/8
  • Rating change
    Analysts Offer Insights on NA Companies: MBX Biosciences, Inc. (MBX), Septerna, Inc. (SEPN) and Six Flags Entertainment Corporation (FUN)
    TipRanks · 2026/8/13
  • Rating change
    Truist Financial Maintains MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $88
    Market Newswire · 2026/8/10
  • HC Wainwright & Co. Initiates Coverage On MBX Biosciences With Buy Rating, Announces Price Target of $90
    Benzinga · 2026/11/12
  • Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $88
    Market Newswire · 2026/10/13
  • UBS Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $90
    Market Newswire · 2026/11/10
  • H.C. Wainwright Initiates MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $90
    Market Newswire · 2026/11/12
  • Truist Financial Maintains MBX Biosciences(MBX.US) With Buy Rating
    Market Newswire · 2026/7/16
  • Rating change
    Analysts Offer Insights on NA Companies: BillionToOne, Inc. Class A (BLLN) and MBX Biosciences, Inc. (MBX)
    TipRanks · 2026/8/7
  • Rating change
    LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $121
    Market Newswire · 2026/8/7
  • Company notice
    MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L.
    SEC · 2026/5/4
  • Rating change
    UBS Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $90
    Market Newswire · 2026/7/24

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

MBX Biosciences discussion 0 comments

Add a comment